A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date30/08/22 → 30/08/27

Keywords

  • phase 3 study
  • Randomised clinical trial
  • breast cancer
  • treatment safety
  • treatment efficacy

Clinical Trial Phase

  • Phase III (a & b)